Skip to content
Affiliates:
Other Sites:  RO Institute  RT Answers
Targeting Cancer Care
News and Media Center
dna_280x186.jpg

Researchers identify DNA sequences that may determine ED following prostate radiation

Researchers have identified 12 DNA sequences that may help doctors determine which men will suffer from erectile dysfunction (ED) following radiation therapy for prostate cancer. Identifying these patients in advance of treatment may better inform men and their families as to which prostate cancer treatments are best for their specific cancer and lifestyle, according to a study to be published online September 27, 2012, in the International Journal of Radiation Oncology•Biology•Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO). The findings could also guide doctors in recommending the most effective treatments that carry the least risk of patients developing ED.

The main treatments for prostate cancer—surgery, brachytherapy (seed implants) and external beam radiation therapy—are all very effective at curing prostate cancer. Unfortunately, each treatment places patients at risk for ED. Although many men will maintain their potency, doctors would like to identify which men are at greatest risk for the development of difficulty with sexual function.

In this multi-institutional, multi-national study, researchers from New York’s Mount Sinai School of Medicine, Albert Einstein College of Medicine of Yeshiva University in Bronx, N.Y., New York University School of Medicine, Florida Radiation Oncology Group in Jacksonville, Fla., and Maastricht University Medical Center in Maastricht, the Netherlands, examined 593 men who were treated with brachytherapy and/or external beam radiation therapy and hormone therapy. Of them, 260 reported erectile dysfunction.

“Through a two-stage genome-wide association study, 12 single nucleotide polymorphisms (SNPs) were identified that were associated with the development of erectile dysfunction after radiation treatment for prostate cancer,” said Barry S. Rosenstein, PhD, department of radiation oncology at New York’s Mount Sinai Medical School. “If validated further, these SNPs could provide the basis for a blood test that would enable radiation oncologists to predict more accurately which men are most likely to develop erectile dysfunction after prostate cancer radiation therapy.”

“Prostate cancer screening and treatment are undergoing major shifts,” said Harry Ostrer, MD, professor of pathology and genetics at Albert Einstein College of Medicine, director of genetic and genomic testing at Montefiore Medical Center and co-principal investigator of the study. “This is part of our ongoing effort to personalize and optimize treatment for prostate cancer.”

Disclosures: One author (NS) reports to have received consulting fees or honoraria from Amgen, Ferring, Janssen, Diversified Conference Management, Prologics LLC, and Nihon MediPhysics. Another author (RS) has received fees for developing lectures and educational materials for Bard.

For complete text of the study, contact Michelle Kirkwood by email or at 703-286-1600. Learn more about the Red Journal.

Content last updated 12/28/2012
About ASTRO | Contact Us | Sitemap | Advertising | Terms of Use | Privacy Policy | My ASTRO | COI Policies | Career Center
News & Media Center | Educational Resources | Meetings and Events | Clinical Practice | Research | Practice Management | Advocacy | Membership
8280 Willow Oaks Corporate Drive, Suite 500, Fairfax, VA 22031 | Phone:703-502-1550 | Toll Free:1-800-962-7876 | Fax:703-502-7852
Copyright © 2014 American Society for Radiation Oncology